Skip to main navigation

Immunocore

Immunocore

Primary Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Document & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact Us

Primary Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Document & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact Us

News Releases

Breadcrumb

  1. Home /
  2. Investor Relations /
  3. News & Events /
  4. News Releases
4 February 2021
Immunocore Announces Pricing of Upsized Initial Public Offering
11 January 2021
Immunocore announces closing of $75.0 Million Series C round
3 December 2020
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
23 November 2020
Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
15 October 2020
Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director
27 August 2020
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
26 May 2020
Immunocore announces dosing of first patient with fourth ImmTAC
6 May 2020
Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy
4 March 2020
First Site in Global Uveal Melanoma Patient Registry Now Open
2 March 2020
Immunocore Secures $130 Million Series B Financing

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Next page next ›
  • Last page last »
Displaying 61 - 70 of 164

Site - Shareholder Tools

Print Page
Email Alerts
RSS Feeds
Email Page

Immunocore

Immunocore

Site - Footer Social

  • About us
  • Our science
  • Our therapy areas
  • For patients
  • News
  • Careers
  • Contact us
  • Privacy and Social Media Guidelines
  • Cookies
  • Payments and Disclosures
  • Clinical trials

©2023 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd